(Total Views: 1027)
Posted On: 08/11/2019 1:20:38 PM
Post# of 154874
He has said multiple times that a company with a NASH drug in clinical trials is worth in the $1-2 billion range.
Do I believe that CYDY’s valuation will jump $1 billion because NASH preclinical results are good? No, I don’t. I honestly don’t think it will move the SP at all, even if a phase 2 is started in NASH. Why? Because at this point unless it’s revenues, non-dilutive financing, or positive cancer results, CYDY is going to stay where it’s at.
Or maybe because I’ve been here for 4+ years I’m conditioned to not seeing any news move the SP and thus I’m unable to accept the possibility of positive SP change? That’s sick if it’s true. Please CYDY, change my mind!
Do I believe that CYDY’s valuation will jump $1 billion because NASH preclinical results are good? No, I don’t. I honestly don’t think it will move the SP at all, even if a phase 2 is started in NASH. Why? Because at this point unless it’s revenues, non-dilutive financing, or positive cancer results, CYDY is going to stay where it’s at.
Or maybe because I’ve been here for 4+ years I’m conditioned to not seeing any news move the SP and thus I’m unable to accept the possibility of positive SP change? That’s sick if it’s true. Please CYDY, change my mind!
(0)
(0)
